ArticleCureus2024
Massive Splenomegaly in Felty's Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Felty's syndrome (FS) is a rare and complex condition most commonly seen as a complication of longstanding rheumatoid arthritis (RA), characterized by a triad of RA, splenomegaly, and neutropenia. Diagnosing FS can be challenging due to its diverse clinical presentations and overlap with other hematologic and autoimmune conditions. We report a 47-year-old male with a history of severe anemia, recurrent blood transfusions, and a chronic leg ulcer. In 2024, he presented with significant weight loss, polyarthralgia, and splenomegaly, prompting concern for a hematologic malignancy. Laboratory findings included elevated beta-2-microglobulin and positive antinuclear antibodies, raising suspicion of lymphoma or other malignancies. Extensive testing ruled out hematologic malignancies and schistosomiasis, and further investigation suggested FS. He was started on prednisone, filgrastim, and methotrexate, leading to substantial clinical improvement, including reduction of joint symptoms, spleen size, and improvement of the leg ulcer. This case highlights the diagnostic complexities of FS, especially in the absence of a prior RA diagnosis. FS should be considered in the differential diagnosis when encountering unexplained splenomegaly and neutropenia, even without a history of chronic RA. Early recognition and treatment can significantly improve patient outcomes. FS, though rare, should be considered in patients presenting with systemic symptoms, cytopenias, and splenomegaly. A thorough diagnostic workup is crucial to differentiate FS from other conditions, particularly hematologic malignancies. This case underscores the importance of prompt diagnosis and treatment to achieve favorable clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.